LivsMed Inc

LivsMed Inc exhibits a capital structure with a low debt-to-equity ratio of 0.06, indicating a conservative leverage profile. The company holds 11.4 billion KRW in cash and equivalents, but its operating cash flow is negative at -34.7 billion KRW, suggesting operational inefficiencies or high working capital demands. The current ratio of 12.68 implies strong short-term liquidity, but the negative free cash flow of -27.9 billion KRW highlights a lack of cash generation from operations. Profitability metrics are severely negative, with a return on equity of -12.65% and a return on assets of -11.33%, both well below the industry median for medical equipment and supplies firms. The company reported a net loss of 22.9 billion KRW and an operating loss of 22.6 billion KRW, indicating a significant decline in operational performance. Gross profit of 29.5 billion KRW is insufficient to cover operating expenses, further underscoring the company's financial distress. LivsMed Inc's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financial report. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes in the South Korean healthcare market. The company's growth trajectory is negative, with no disclosed revenue growth in the most recent fiscal year. Analysts have assigned a mean price target of 140,000 KRW, but the lack of strong buy ratings and the presence of only one buy recommendation suggest limited investor confidence. The company's capital expenditure of -7.7 billion KRW indicates a reduction in investment, which may hinder long-term growth prospects. LivsMed Inc faces medium liquidity risk due to its negative operating cash flow and free cash flow. The risk assessment indicates low dilution potential, but the negative net cash position after subtracting total debt raises concerns about the company's ability to meet short-term obligations. No recent filings or transcripts have been disclosed that provide additional insight into the company's strategic direction or operational challenges. The company's recent financial performance and lack of diversification suggest a high concentration risk, as it is heavily reliant on a single business model and geographic market. Regulatory risk is moderate, given the company's exposure to the South Korean healthcare sector, which is subject to policy changes and reimbursement pressures.